Dr. Kurz joins eXIthera as the Vice President of Translational Medicine and Medical Affairs Westborough, Mass., June 25, 2019 – eXIthera Pharmaceuticals, a clinical-stage biotechnology company focused on addressing bleeding complications through the inhibition of Factor XIa, today announced the appointment of Michael Kurz, Ph.D., to the company’s leadership team. Dr. Kurz will join […]
eXIthera is doing big things with small molecules. This clinical-stage biotech company is developing therapies to maintain the balance between healthy blood flow and clotting, specifically during heart surgery. In today’s Cutting Edge Cast, eXIthera CEO Neil Hayward, Ph.D., explains why this therapy is critical for patients.
EP-7041 is a novel, potent, selective small molecule FXIa inhibitor designed to prevent thrombosis with limited risk for bleeding side effects. Results from the Phase 1a/1b study were highlighted in a poster presentation on Nov. 13 at the American Heart Association (AHA) Scientific Sessions 2017, in Anaheim, California.
eXIthera Pharmaceuticals Inc. CEO Neil Hayward told BioWorld he's hoping to build a "continuum of care" around factor XIa inhibitor EP-7041, after Phase I data showed the intravenous (I.V.) version of the antithrombotic safe and well-tolerated in healthy volunteers after single or multiple ascending intravenous doses – and even turned up some clues to efficacy.
Phase 1a/1b Study of EP-7041: A Novel, Potent, Selective, Small Molecule FXIa Inhibitor
Phase 1 results suggest the PK/PD profile of EP-7041 is ideal in acute care hospital settings where patients are at risk of thromboembolic events.Download as PDF